- Purvalanol A
-
- $33.00 / 5mg
-
2026-03-13
- CAS:212844-53-6
- Min. Order:
- Purity: 99.68%
- Supply Ability: 10g
- PURVALANOL A
-
- $1.00 / 1KG
-
2019-09-06
- CAS:212844-53-6
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 20kg
|
| | PURVALANOL A Basic information |
| Product Name: | PURVALANOL A | | Synonyms: | PURVALANOL A;NG-60;6-(3-CHLOROANILINO)-2(1R)-ISOPROPYL-2-HYDROXYETHYLAMINO-9-ISOPROPYLPURINE;(2R)-2-[[6-[(3-CHLOROPHENYL)AMINO]-9-(1-METHYLETHYL)-9H-PURIN-2-YL]AMINO]-3-METHYL-1-BUTANOL;2-(1R-ISOPROPOYL-2-HYDROXYETHYLAMINO)-6-(3-CHLOROANILINO)-9-ISOPROPYLPURINE;2-(1R-ISOPROPYL-2-HYDROXYETHYLAMINO)-6-(3-CHLOROANILINO)-9-ISOPROPYL-PURINE;CH61386;2R)-2-[[6-[(3-Chlorophenyl)amino]-9-(1-methylethyl)-9H-purin-2-yl]amino]-3-methyl-1-butanolCDKinhibitor. | | CAS: | 212844-53-6 | | MF: | C19H25ClN6O | | MW: | 388.89 | | EINECS: | | | Product Categories: | Inhibitors;Signalling | | Mol File: | 212844-53-6.mol |  |
| | PURVALANOL A Chemical Properties |
| Boiling point | 590.5±60.0 °C(Predicted) | | density | 1.33±0.1 g/cm3(Predicted) | | storage temp. | Keep in dark place,Inert atmosphere,Store in freezer, under -20°C | | solubility | methylene chloride: 50 mg/mL, clear, colorless | | form | powder | | pka | 14.51±0.10(Predicted) | | color | off-white | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months. | | InChI | 1S/C19H25ClN6O/c1-11(2)15(9-27)23-19-24-17(22-14-7-5-6-13(20)8-14)16-18(25-19)26(10-21-16)12(3)4/h5-8,10-12,15,27H,9H2,1-4H3,(H2,22,23,24,25)/t15-/m0/s1 | | InChIKey | PMXCMJLOPOFPBT-HNNXBMFYSA-N | | SMILES | Clc1cc(ccc1)Nc2nc(nc3[n](cnc32)C(C)C)N[C@@H](CO)C(C)C |
| WGK Germany | 3 | | HS Code | 2933599590 | | Storage Class | 11 - Combustible Solids |
| | PURVALANOL A Usage And Synthesis |
| Description | Purvalanol A (212844-53-6) is a cyclin-dependent kinase inhibitor. IC50s= 4, 70, 35, 75 and 850 nM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, cdk5/p35 and cdk4/cyclin D1 and respectively.1Reversibly arrests synchronized cells in G1 and G2 phase.2Induces ER stress-mediated apoptosis and autophagy in colon cancer cells.3Suppresses Src-mediated transformation by inhibiting both CDKs and c-Src.4In cells transformed with MYC, purvalanol A rapidly down-regulates survivin expression and induces MYC-dependent apoptosis.5Cell permeable. | | Uses | Purvalanol A acts as a potent, cell-permeable CDK inhibitor used in the treatment of cell proliferative disorders. Anti-cancer. | | Definition | ChEBI: Purvalanol A is a purvalanol. | | Biological Activity | Cyclin-dependent kinase inhibitor. IC 50 values are 4, 70, 35, 850 and 75 nM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, cdk4/cyclin D1 and cdk5-p35 respectively. Reversibly arrests synchronised cells in G1 and G2, and inhibits cell proliferation and cell death. | | storage | Store at +4°C | | References | [1] SERA T. [Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors].[J]. Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, 2007, 52 13 Suppl: 1812-1813.
[2] NATHALIE VILLERBU. Cellular effects of purvalanol A: A specific inhibitor of cyclin-dependent kinase activities[J]. International Journal of Cancer, 2001, 97 6: 761-769. DOI:10.1002/ijc.10125
[3] AJDA COKER-GÜRKAN. Purvalanol induces endoplasmic reticulum stress-mediated apoptosis and autophagy in a time-dependent manner in HCT116 colon cancer cells.[J]. Oncology reports, 2015: 2761-2770. DOI:10.3892/or.2015.3918
[4] TOMOYA HIKITA Masato O Chitose Oneyama. Purvalanol A, a CDK inhibitor, effectively suppresses Src-mediated transformation by inhibiting both CDKs and c-Src.[J]. Genes to Cells, 2010, 15 10: 1051-1062. DOI:10.1111/j.1365-2443.2010.01439.x
[5] ANDREI GOGA. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC[J]. Nature Medicine, 2007, 13 7: 820-827. DOI:10.1038/nm1606 |
| | PURVALANOL A Preparation Products And Raw materials |
|